Celcuity Inc. (NASDAQ:CELC) Short Interest Update

Celcuity Inc. (NASDAQ:CELC - Get Free Report) saw a significant decline in short interest in November. As of November 30th, there was short interest totalling 2,870,000 shares, a decline of 7.1% from the November 15th total of 3,090,000 shares. Based on an average daily volume of 263,800 shares, the short-interest ratio is presently 10.9 days.

Analysts Set New Price Targets

A number of analysts have commented on the company. Stifel Nicolaus upped their price target on Celcuity from $39.00 to $42.00 and gave the stock a "buy" rating in a research report on Monday, October 7th. Lifesci Capital started coverage on shares of Celcuity in a report on Monday, August 26th. They issued an "outperform" rating and a $27.00 target price for the company. Needham & Company LLC restated a "buy" rating and set a $23.00 target price on shares of Celcuity in a research note on Friday, November 15th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $27.00 price target on shares of Celcuity in a report on Friday, November 15th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $29.17.

Celcuity Price Performance

CELC traded up $0.03 on Monday, hitting $12.55. 805,868 shares of the company's stock traded hands, compared to its average volume of 277,174. The company's 50 day simple moving average is $14.34 and its 200-day simple moving average is $15.48. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. Celcuity has a one year low of $11.51 and a one year high of $22.19. The firm has a market cap of $465.98 million, a price-to-earnings ratio of -4.81 and a beta of 0.74.

Institutional Investors Weigh In On Celcuity

Several institutional investors and hedge funds have recently modified their holdings of CELC. nVerses Capital LLC purchased a new stake in shares of Celcuity in the third quarter worth about $33,000. Prospera Private Wealth LLC bought a new stake in Celcuity in the 3rd quarter worth approximately $35,000. Values First Advisors Inc. purchased a new stake in shares of Celcuity during the 3rd quarter worth approximately $86,000. Quest Partners LLC boosted its position in shares of Celcuity by 31.3% during the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company's stock valued at $95,000 after acquiring an additional 1,379 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Celcuity during the 3rd quarter valued at approximately $119,000. Institutional investors own 63.33% of the company's stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.